Multiple Oral Dosings, Cross-over Design Clinical Trial to Evaluate the Safety and Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers
Multiple Oral Dosings, Cross-over Design Clinical Trial to Evaluate the Safety and Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers
To evaluate the interaction between two investigational products by comparing and analyzing
 pharmacokinetic interactions and safety in steady state after multiple oral administration of
 ATB-1011 or ATB-1012 alone or in combination in healthy adult volunteers.
-  Arm A: To evaluate the effect of ATB-1012 on the safety and pharmacokinetic properties
 of ATB-1011 in steady state.

 -  Arm B: To evaluate the effect of ATB-1011 on the safety and pharmacokinetic properties
 of ATB-1012 in steady state.
Inclusion Criteria:

 1. Those who are over 19 years old at the screening visit

 2. Those with a body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 with a weight of
 50 kg or more (45 kg or more for women) at the screening visit

 3. Those who do not have clinically significant congenital or chronic diseases and have
 no pathological symptoms or findings upon medical examination at the screening visit

 4. Those who determined as suitable study subjects by the principal investigator (or a
 delegated sub-investigator) in result of planned and conducted laboratory tests such
 as hematology, blood chemistry, serum, and urine tests according to the
 characteristics of the investigational product.

 Exclusion Criteria:

 - 1) Those who have a clinically significant disease or have a history of such disease in
 the digestive system, cardiovascular system, endocrine system, respiratory system,
 blood/tumor, infectious diseases, kidney and genitourinary system, mental and nervous
 system, musculoskeletal system, immune system, otorhinolaryngology, skin system and
 ophthalmic system.

 2) Those who have a history of gastrointestinal surgery (except for simple appendectomy or
 hernia surgery) that may affect the absorption of drugs or have gastrointestinal diseases
 3) Those who have taken drugs that induce and inhibit metabolism enzymes such as barbital
 drugs within 1 month of the first administration date, or have taken drugs that may
 interfere with this clinical trial within 10 days of the first administration date.
 (However, participation is possible depending on the characteristics of pharmacokinetics
 and pharmacodynamics such as interactions with investigational products or half-life of
 concomitant drugs) 4) Those who participated in other clinical trials or bioequivalence
 studies and administered the investigational products within 6 months of the first
 administration date.